These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11714470)

  • 21. Reimbursable drug classes and ceilings in Italy: why not only one?
    Garattini L; Curto A; Padula A
    Eur J Health Econ; 2016 Nov; 17(8):923-926. PubMed ID: 27255742
    [No Abstract]   [Full Text] [Related]  

  • 22. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International price comparisons for novel and follow-on drugs.
    Ridley DB
    Value Health; 2007; 10(6):510-1; discussion 512-3. PubMed ID: 17970933
    [No Abstract]   [Full Text] [Related]  

  • 24. PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric.
    Grocott R; Metcalfe S
    N Z Med J; 2012 Jul; 125(1358):89-90. PubMed ID: 22864151
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cost-minimisation analysis of the pharmacological treatment of epilepsy in Spain].
    Rubio M; Lizán L; Badia X; Escartín-Siquier AE; López-Trigo J; Rufo-Campos M; Echarri E
    Rev Neurol; 2006 Mar 1-15; 42(5):257-64. PubMed ID: 16538587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [No funds for contract physicians and drugs. However, deceased mental healers fill the cash registers].
    Rautenstrauch J
    MMW Fortschr Med; 2000 Nov; 142(47):4-5. PubMed ID: 11143779
    [No Abstract]   [Full Text] [Related]  

  • 27. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
    Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacoeconomics and cost of cancer drugs].
    Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
    Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
    Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
    Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
    Hsieh CR; Sloan FA
    Value Health; 2008; 11(2):334-44. PubMed ID: 18380646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-containment measures in the Italian healthcare system.
    Mapelli V
    Pharmacoeconomics; 1995 Aug; 8(2):85-90. PubMed ID: 10155613
    [No Abstract]   [Full Text] [Related]  

  • 34. Propaganda or the cost of innovation? Challenging the high price of new drugs.
    Ghinea N; Lipworth W; Kerridge I
    BMJ; 2016 Mar; 352():i1284. PubMed ID: 26968991
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost containment, drugs and community health.
    Wiesner D
    Aust J Public Health; 1995 Dec; 19(6):641-2. PubMed ID: 8616208
    [No Abstract]   [Full Text] [Related]  

  • 36. Comment on "Where's the value in health care"?
    Lungen M; Gerber A
    Value Health; 2007; 10(2):170; author reply 171. PubMed ID: 17391426
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmaceutical expenditure among primary care physicians in the health area of Cuenca (Spain). Response].
    Segura Benito MJ; Moya Martínez P; Escribano Sotos F
    Gac Sanit; 2012; 26(4):389-90. PubMed ID: 22361640
    [No Abstract]   [Full Text] [Related]  

  • 38. [Application of pharmacoeconomics in clinical management].
    Amat Díaz M; Poveda Andrés JL; Carrera-Hueso FJ
    Farm Hosp; 2011 May; 35 Suppl 2():18-24. PubMed ID: 22445505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
    Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The budget control function of the Drug Reimbursement System].
    Pronk MH; Bonsel GJ; van der Kuy A
    Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1729-33. PubMed ID: 12357873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.